Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects
The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h). The tyramine sensitivity factor (TSF) was calculated from the ratio of baseline and on‐treatment tyramine pressor doses. The tyramine sensitivity factor value foll...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacology 2006-08, Vol.46 (8), p.933-944 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 944 |
|---|---|
| container_issue | 8 |
| container_start_page | 933 |
| container_title | Journal of clinical pharmacology |
| container_volume | 46 |
| creator | Azzaro, Albert J. VanDenBerg, Chad M. Blob, Lawrence F. Kemper, Eva M. Sharoky, Melvin Oren, Dan A. Campbell, Bryan J. |
| description | The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h). The tyramine sensitivity factor (TSF) was calculated from the ratio of baseline and on‐treatment tyramine pressor doses. The tyramine sensitivity factor value following 9 days of treatment with the selegiline transdermal system was 1.85 ± 0.10. Extended treatment, 33 days, produced a small, clinically nonmeaningful increase in this value. The tyramine sensitivity factor for the selegiline transdermal system was similar to that following treatment with 10 mg/d of oral selegiline capsules but more than 20 times less than observed during tranylcypromine treatment. A larger increase in the tyramine sensitivity factor was observed following extended selegiline transdermal system treatment at a higher dose (12 mg/24 h), which was significantly decreased following coadministration of tyramine capsules with a meal. These results suggest a wide tyramine safety margin for the selegiline transdermal system and provide evidence that the 6‐mg/24‐h selegiline transdermal system can be administered safely without dietary tyramine restrictions. |
| doi_str_mv | 10.1177/0091270006289852 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A148425047</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A148425047</galeid><sourcerecordid>A148425047</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4650-192c75dea21abd33f6246bba511c04974de1692bfd5ba01c0be2f2cbbd470e143</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxSMEokvhzgn5C6QdO_6THKuFdqmqUmkXerTsZLJxm2Qr20vJt8dLVlTigizL8rz5PY-es-wjhTNKlToHqChTACBZWZWCvcoWVAiWcwn8dbY4yPlBP8nehfAAQCUX9G12QmUpBKhykfnN5M3gRiR3HkPYebLGMbjofro4kc9778Yt2Xg0ccAxknsXOxI7TF09bl1_ADfejKFBP5ierKcQcSCSDNtzxklH3EhWaPrYTWS9tw9Yx_A-e9OaPuCH43mafb_8slmu8ptvV1-XFzd5zaWAnFasVqJBw6ixTVG0knFprRGU1sArxRuksmK2bYQ1kGoWWctqaxuuACkvTrOz2XdretRubHfRmzqtBgdX70ZsXapfUF5yJoCrBMAM1H4XgsdWP3k3GD9pCvqQt_4374R8mpGnvR2weQGOAacGPjc87_qIPjz2-2f0uvuTSfKD9DBAzpIllOmWp00hYeKIpRmn_86hr5d3K6mKxOUz59I__PrLGf-ok6yEvr-90nKtriW7pPpH8RtZK6jK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Azzaro, Albert J. ; VanDenBerg, Chad M. ; Blob, Lawrence F. ; Kemper, Eva M. ; Sharoky, Melvin ; Oren, Dan A. ; Campbell, Bryan J.</creator><creatorcontrib>Azzaro, Albert J. ; VanDenBerg, Chad M. ; Blob, Lawrence F. ; Kemper, Eva M. ; Sharoky, Melvin ; Oren, Dan A. ; Campbell, Bryan J.</creatorcontrib><description>The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h). The tyramine sensitivity factor (TSF) was calculated from the ratio of baseline and on‐treatment tyramine pressor doses. The tyramine sensitivity factor value following 9 days of treatment with the selegiline transdermal system was 1.85 ± 0.10. Extended treatment, 33 days, produced a small, clinically nonmeaningful increase in this value. The tyramine sensitivity factor for the selegiline transdermal system was similar to that following treatment with 10 mg/d of oral selegiline capsules but more than 20 times less than observed during tranylcypromine treatment. A larger increase in the tyramine sensitivity factor was observed following extended selegiline transdermal system treatment at a higher dose (12 mg/24 h), which was significantly decreased following coadministration of tyramine capsules with a meal. These results suggest a wide tyramine safety margin for the selegiline transdermal system and provide evidence that the 6‐mg/24‐h selegiline transdermal system can be administered safely without dietary tyramine restrictions.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1177/0091270006289852</identifier><identifier>PMID: 16855078</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Cutaneous ; Administration, Oral ; Adolescent ; Adult ; Blood Pressure - drug effects ; Complications and side effects ; Cross-Over Studies ; depression ; Depression, Mental ; Dosage and administration ; Dose-Response Relationship, Drug ; Drug therapy ; Food-Drug Interactions ; Heart Rate - drug effects ; Humans ; Hypertension - chemically induced ; Hypertension - physiopathology ; Male ; Middle Aged ; Monoamine oxidase ; monoamine oxidase inhibitor ; Monoamine Oxidase Inhibitors - administration & dosage ; Monoamine Oxidase Inhibitors - adverse effects ; Reference Values ; Selegiline ; Selegiline - administration & dosage ; Selegiline - adverse effects ; Testing ; Time Factors ; transdermal ; Transdermal medication ; Tranylcypromine - administration & dosage ; Tranylcypromine - adverse effects ; Tyramine - administration & dosage ; Tyramine - adverse effects ; tyramine pressor test</subject><ispartof>Journal of clinical pharmacology, 2006-08, Vol.46 (8), p.933-944</ispartof><rights>2006 American College of Clinical Pharmacology</rights><rights>2006 SAGE Publications</rights><rights>COPYRIGHT 2006 Sage Publications, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4650-192c75dea21abd33f6246bba511c04974de1692bfd5ba01c0be2f2cbbd470e143</citedby><cites>FETCH-LOGICAL-c4650-192c75dea21abd33f6246bba511c04974de1692bfd5ba01c0be2f2cbbd470e143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1177%2F0091270006289852$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1177%2F0091270006289852$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16855078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azzaro, Albert J.</creatorcontrib><creatorcontrib>VanDenBerg, Chad M.</creatorcontrib><creatorcontrib>Blob, Lawrence F.</creatorcontrib><creatorcontrib>Kemper, Eva M.</creatorcontrib><creatorcontrib>Sharoky, Melvin</creatorcontrib><creatorcontrib>Oren, Dan A.</creatorcontrib><creatorcontrib>Campbell, Bryan J.</creatorcontrib><title>Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h). The tyramine sensitivity factor (TSF) was calculated from the ratio of baseline and on‐treatment tyramine pressor doses. The tyramine sensitivity factor value following 9 days of treatment with the selegiline transdermal system was 1.85 ± 0.10. Extended treatment, 33 days, produced a small, clinically nonmeaningful increase in this value. The tyramine sensitivity factor for the selegiline transdermal system was similar to that following treatment with 10 mg/d of oral selegiline capsules but more than 20 times less than observed during tranylcypromine treatment. A larger increase in the tyramine sensitivity factor was observed following extended selegiline transdermal system treatment at a higher dose (12 mg/24 h), which was significantly decreased following coadministration of tyramine capsules with a meal. These results suggest a wide tyramine safety margin for the selegiline transdermal system and provide evidence that the 6‐mg/24‐h selegiline transdermal system can be administered safely without dietary tyramine restrictions.</description><subject>Administration, Cutaneous</subject><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Blood Pressure - drug effects</subject><subject>Complications and side effects</subject><subject>Cross-Over Studies</subject><subject>depression</subject><subject>Depression, Mental</subject><subject>Dosage and administration</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Food-Drug Interactions</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Hypertension - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoamine oxidase</subject><subject>monoamine oxidase inhibitor</subject><subject>Monoamine Oxidase Inhibitors - administration & dosage</subject><subject>Monoamine Oxidase Inhibitors - adverse effects</subject><subject>Reference Values</subject><subject>Selegiline</subject><subject>Selegiline - administration & dosage</subject><subject>Selegiline - adverse effects</subject><subject>Testing</subject><subject>Time Factors</subject><subject>transdermal</subject><subject>Transdermal medication</subject><subject>Tranylcypromine - administration & dosage</subject><subject>Tranylcypromine - adverse effects</subject><subject>Tyramine - administration & dosage</subject><subject>Tyramine - adverse effects</subject><subject>tyramine pressor test</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxSMEokvhzgn5C6QdO_6THKuFdqmqUmkXerTsZLJxm2Qr20vJt8dLVlTigizL8rz5PY-es-wjhTNKlToHqChTACBZWZWCvcoWVAiWcwn8dbY4yPlBP8nehfAAQCUX9G12QmUpBKhykfnN5M3gRiR3HkPYebLGMbjofro4kc9778Yt2Xg0ccAxknsXOxI7TF09bl1_ADfejKFBP5ierKcQcSCSDNtzxklH3EhWaPrYTWS9tw9Yx_A-e9OaPuCH43mafb_8slmu8ptvV1-XFzd5zaWAnFasVqJBw6ixTVG0knFprRGU1sArxRuksmK2bYQ1kGoWWctqaxuuACkvTrOz2XdretRubHfRmzqtBgdX70ZsXapfUF5yJoCrBMAM1H4XgsdWP3k3GD9pCvqQt_4374R8mpGnvR2weQGOAacGPjc87_qIPjz2-2f0uvuTSfKD9DBAzpIllOmWp00hYeKIpRmn_86hr5d3K6mKxOUz59I__PrLGf-ok6yEvr-90nKtriW7pPpH8RtZK6jK</recordid><startdate>200608</startdate><enddate>200608</enddate><creator>Azzaro, Albert J.</creator><creator>VanDenBerg, Chad M.</creator><creator>Blob, Lawrence F.</creator><creator>Kemper, Eva M.</creator><creator>Sharoky, Melvin</creator><creator>Oren, Dan A.</creator><creator>Campbell, Bryan J.</creator><general>Blackwell Publishing Ltd</general><general>SAGE Publications</general><general>Sage Publications, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200608</creationdate><title>Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects</title><author>Azzaro, Albert J. ; VanDenBerg, Chad M. ; Blob, Lawrence F. ; Kemper, Eva M. ; Sharoky, Melvin ; Oren, Dan A. ; Campbell, Bryan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4650-192c75dea21abd33f6246bba511c04974de1692bfd5ba01c0be2f2cbbd470e143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Administration, Cutaneous</topic><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Blood Pressure - drug effects</topic><topic>Complications and side effects</topic><topic>Cross-Over Studies</topic><topic>depression</topic><topic>Depression, Mental</topic><topic>Dosage and administration</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Food-Drug Interactions</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Hypertension - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoamine oxidase</topic><topic>monoamine oxidase inhibitor</topic><topic>Monoamine Oxidase Inhibitors - administration & dosage</topic><topic>Monoamine Oxidase Inhibitors - adverse effects</topic><topic>Reference Values</topic><topic>Selegiline</topic><topic>Selegiline - administration & dosage</topic><topic>Selegiline - adverse effects</topic><topic>Testing</topic><topic>Time Factors</topic><topic>transdermal</topic><topic>Transdermal medication</topic><topic>Tranylcypromine - administration & dosage</topic><topic>Tranylcypromine - adverse effects</topic><topic>Tyramine - administration & dosage</topic><topic>Tyramine - adverse effects</topic><topic>tyramine pressor test</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azzaro, Albert J.</creatorcontrib><creatorcontrib>VanDenBerg, Chad M.</creatorcontrib><creatorcontrib>Blob, Lawrence F.</creatorcontrib><creatorcontrib>Kemper, Eva M.</creatorcontrib><creatorcontrib>Sharoky, Melvin</creatorcontrib><creatorcontrib>Oren, Dan A.</creatorcontrib><creatorcontrib>Campbell, Bryan J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azzaro, Albert J.</au><au>VanDenBerg, Chad M.</au><au>Blob, Lawrence F.</au><au>Kemper, Eva M.</au><au>Sharoky, Melvin</au><au>Oren, Dan A.</au><au>Campbell, Bryan J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2006-08</date><risdate>2006</risdate><volume>46</volume><issue>8</issue><spage>933</spage><epage>944</epage><pages>933-944</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><abstract>The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h). The tyramine sensitivity factor (TSF) was calculated from the ratio of baseline and on‐treatment tyramine pressor doses. The tyramine sensitivity factor value following 9 days of treatment with the selegiline transdermal system was 1.85 ± 0.10. Extended treatment, 33 days, produced a small, clinically nonmeaningful increase in this value. The tyramine sensitivity factor for the selegiline transdermal system was similar to that following treatment with 10 mg/d of oral selegiline capsules but more than 20 times less than observed during tranylcypromine treatment. A larger increase in the tyramine sensitivity factor was observed following extended selegiline transdermal system treatment at a higher dose (12 mg/24 h), which was significantly decreased following coadministration of tyramine capsules with a meal. These results suggest a wide tyramine safety margin for the selegiline transdermal system and provide evidence that the 6‐mg/24‐h selegiline transdermal system can be administered safely without dietary tyramine restrictions.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16855078</pmid><doi>10.1177/0091270006289852</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-2700 |
| ispartof | Journal of clinical pharmacology, 2006-08, Vol.46 (8), p.933-944 |
| issn | 0091-2700 1552-4604 |
| language | eng |
| recordid | cdi_gale_infotracacademiconefile_A148425047 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Administration, Cutaneous Administration, Oral Adolescent Adult Blood Pressure - drug effects Complications and side effects Cross-Over Studies depression Depression, Mental Dosage and administration Dose-Response Relationship, Drug Drug therapy Food-Drug Interactions Heart Rate - drug effects Humans Hypertension - chemically induced Hypertension - physiopathology Male Middle Aged Monoamine oxidase monoamine oxidase inhibitor Monoamine Oxidase Inhibitors - administration & dosage Monoamine Oxidase Inhibitors - adverse effects Reference Values Selegiline Selegiline - administration & dosage Selegiline - adverse effects Testing Time Factors transdermal Transdermal medication Tranylcypromine - administration & dosage Tranylcypromine - adverse effects Tyramine - administration & dosage Tyramine - adverse effects tyramine pressor test |
| title | Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T10%3A25%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tyramine%20Pressor%20Sensitivity%20During%20Treatment%20With%20the%20Selegiline%20Transdermal%20System%206%20mg/24%20h%20in%20Healthy%20Subjects&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Azzaro,%20Albert%20J.&rft.date=2006-08&rft.volume=46&rft.issue=8&rft.spage=933&rft.epage=944&rft.pages=933-944&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1177/0091270006289852&rft_dat=%3Cgale_cross%3EA148425047%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16855078&rft_galeid=A148425047&rfr_iscdi=true |